You are visiting a website that is not intended for your region

The page or information you have requested is intended for an audience outside the United States. By continuing to browse you confirm that you are a non-US resident requesting access to this page or information.

Switch to the US site

Select Your Country or Region
Send
COVID-19 Resource Center

Nyheder

Getinge confirms earnings forecasts for 2012

Getinge confirms earnings forecasts for 2012

For a considerable number of years, the Getinge Group’s full-year earnings and volume-trend forecasts have demonstrated a very high level of precision. At the same time, earnings for individual quarters and business areas may present substantial variation in terms of both the volume trend and earnings growth.

In a comparison between the Group’s preliminary earnings for the first quarter of 2012 and the market’s expected earnings outcome, a significant deviation was confirmed, thus motivating the publication of this press release. The Group’s profit before tax for the first quarter of 2012 will be between SEK 560 million and SEK 570 million, which is in line with profit for the year-earlier period. Volume growth for the Group in terms of orders received and invoicing both experienced low single-digit organic growth.

The outcome for the first quarter of the year has in no way impacted the Group’s expectations in terms of earnings and volume growth for the full-year 2012. The Getinge Group continues to anticipate an improvement in organic invoicing growth in 2012 compared with 2011, and that profit growth will remain favourable.

For further information:
Johan Malmquist, President and CEO
Ulf Grunander, CFO
Telephone: +46 (0)10-335 00 00

GETINGE GROUP is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and MAQUET. ArjoHuntleigh focuses on patient mobility and wound management solutions. GETINGE provides solutions for infection control within healthcare and contamination prevention within life sciences. MAQUET specializes in solutions, therapies and products for surgical interventions and intensive care.

The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.

Files

Del: